The estimated Net Worth of John J Greisch is at least $12.7 Millón dollars as of 30 August 2023. Mr. Greisch owns over 21,000 units of Catalent stock worth over $2,027,420 and over the last 20 years he sold CTLT stock worth over $10,388,526. In addition, he makes $299,975 as Independent Director at Catalent.
John has made over 25 trades of the Catalent stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 21,000 units of CTLT stock worth $1,055,040 on 30 August 2023.
The largest trade he's ever made was exercising 207,987 units of Catalent stock on 3 March 2017 worth over $4,975,049. On average, John trades about 17,662 units every 102 days since 2004. As of 30 August 2023 he still owns at least 34,000 units of Catalent stock.
You can see the complete history of Mr. Greisch stock trades at the bottom of the page.
John J. Greisch is Independent Director of the Company. Mr. Greisch retired in May 2018 from his position as President and Chief Executive Officer of Hill-Rom Holdings, Inc., a position that he had held since 2010. Prior to that, Mr. Greisch was President International Operations for Baxter International, Inc., a position he held beginning in 2006. During his seven-year tenure with Baxter, he also served as the company’s Chief Financial Officer and as President of its BioScience division. Before his time with Baxter, Mr. Greisch was President and Chief Executive Officer for FleetPride Corporation in Deerfield, Illinois, an independent after-market distribution company serving the transportation industry. Prior to his tenure at FleetPride, he held various positions at The Interlake Corporation, including serving as President of its Materials Handling Group. Mr. Greisch currently serves as chairman of the board of Viant Medical, LLC and as a director on the board of Idorsia Pharmaceuticals Ltd. and Cerner Corporation, and previously served on the boards of Hill-Rom Holdings, Inc., Actelion Ltd, and TomoTherapy, Inc. Additionally, he serves as a senior advisor to TPG Capital and is on the board of directors for Ann & Robert H. Lurie Children’s Hospital of Chicago. He received a Master’s in Management from the Kellogg School of Management at Northwestern University and a B.S. degree from Miami University.
As the Independent Director of Catalent, the total compensation of John Greisch at Catalent is $299,975. There are 12 executives at Catalent getting paid more, with John Chiminski having the highest compensation of $8,514,990.
John Greisch is 64, he's been the Independent Director of Catalent since 2018. There are 4 older and 23 younger executives at Catalent. The oldest executive at Catalent Inc. is Rolf Classon, 75, who is the Independent Director.
John's mailing address filed with the SEC is Pasteur Boulevard, Palm Beach Gardens, Palm Beach County, Florida, 33418, United States.
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius y Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: